FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R)
Se refiere a una formulacion farmaceutica que comprende: (i) un anticuerpo humano que se une de modo especifico al receptor de interleuquina-6-humana (hIL-6R) a una concentracion de 25 mg/ml a 200 mg/ml y comprende una region variable donde la cadena pesada comprende la secuencia SEQ ID NO: 18 y la...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GRAHAM, Kenneth S WALSH, Scott M DIX, Daniel B KAMEN, Douglas E |
| description | Se refiere a una formulacion farmaceutica que comprende: (i) un anticuerpo humano que se une de modo especifico al receptor de interleuquina-6-humana (hIL-6R) a una concentracion de 25 mg/ml a 200 mg/ml y comprende una region variable donde la cadena pesada comprende la secuencia SEQ ID NO: 18 y la cadena ligera, la secuencia SEQ ID NO: 26; (ii) histidina a una concentracion de 10 mM a 25 mM; (iii) arginina a una concentracion de 25 mM a 50 mM; (iv) sacarosa en una cantidad de 5% a 10 %; y (v) polisorbato 20 en una cantidad de 0,2%. Dicha formulacion muestra un grado sustancial de estabilidad del anticuerpo despues de una conservacion durante varios meses
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PE20170948A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PE20170948A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PE20170948A13</originalsourceid><addsrcrecordid>eNqNyr0KwjAUQOEuDqK-w3XTIdCqVB2v6S1eiEman8XBUiROooX6_ijiAzidbzjj7FIbd4oKJRtNHsgHPLDiM1booYkE0ujApEkDfiAjOWv818KRJBuMg4qAdSCnKDaRNYoSFqxE6ZbTbHTr7kOa_TrJ5jUFeRSpf7Zp6LtreqRXa2mVF9t8v9lhsf7neQM6EDLp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R)</title><source>esp@cenet</source><creator>GRAHAM, Kenneth S ; WALSH, Scott M ; DIX, Daniel B ; KAMEN, Douglas E</creator><creatorcontrib>GRAHAM, Kenneth S ; WALSH, Scott M ; DIX, Daniel B ; KAMEN, Douglas E</creatorcontrib><description>Se refiere a una formulacion farmaceutica que comprende: (i) un anticuerpo humano que se une de modo especifico al receptor de interleuquina-6-humana (hIL-6R) a una concentracion de 25 mg/ml a 200 mg/ml y comprende una region variable donde la cadena pesada comprende la secuencia SEQ ID NO: 18 y la cadena ligera, la secuencia SEQ ID NO: 26; (ii) histidina a una concentracion de 10 mM a 25 mM; (iii) arginina a una concentracion de 25 mM a 50 mM; (iv) sacarosa en una cantidad de 5% a 10 %; y (v) polisorbato 20 en una cantidad de 0,2%. Dicha formulacion muestra un grado sustancial de estabilidad del anticuerpo despues de una conservacion durante varios meses
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170713&DB=EPODOC&CC=PE&NR=20170948A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170713&DB=EPODOC&CC=PE&NR=20170948A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GRAHAM, Kenneth S</creatorcontrib><creatorcontrib>WALSH, Scott M</creatorcontrib><creatorcontrib>DIX, Daniel B</creatorcontrib><creatorcontrib>KAMEN, Douglas E</creatorcontrib><title>FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R)</title><description>Se refiere a una formulacion farmaceutica que comprende: (i) un anticuerpo humano que se une de modo especifico al receptor de interleuquina-6-humana (hIL-6R) a una concentracion de 25 mg/ml a 200 mg/ml y comprende una region variable donde la cadena pesada comprende la secuencia SEQ ID NO: 18 y la cadena ligera, la secuencia SEQ ID NO: 26; (ii) histidina a una concentracion de 10 mM a 25 mM; (iii) arginina a una concentracion de 25 mM a 50 mM; (iv) sacarosa en una cantidad de 5% a 10 %; y (v) polisorbato 20 en una cantidad de 0,2%. Dicha formulacion muestra un grado sustancial de estabilidad del anticuerpo despues de una conservacion durante varios meses
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyr0KwjAUQOEuDqK-w3XTIdCqVB2v6S1eiEman8XBUiROooX6_ijiAzidbzjj7FIbd4oKJRtNHsgHPLDiM1booYkE0ujApEkDfiAjOWv818KRJBuMg4qAdSCnKDaRNYoSFqxE6ZbTbHTr7kOa_TrJ5jUFeRSpf7Zp6LtreqRXa2mVF9t8v9lhsf7neQM6EDLp</recordid><startdate>20170713</startdate><enddate>20170713</enddate><creator>GRAHAM, Kenneth S</creator><creator>WALSH, Scott M</creator><creator>DIX, Daniel B</creator><creator>KAMEN, Douglas E</creator><scope>EVB</scope></search><sort><creationdate>20170713</creationdate><title>FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R)</title><author>GRAHAM, Kenneth S ; WALSH, Scott M ; DIX, Daniel B ; KAMEN, Douglas E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PE20170948A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2017</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>GRAHAM, Kenneth S</creatorcontrib><creatorcontrib>WALSH, Scott M</creatorcontrib><creatorcontrib>DIX, Daniel B</creatorcontrib><creatorcontrib>KAMEN, Douglas E</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GRAHAM, Kenneth S</au><au>WALSH, Scott M</au><au>DIX, Daniel B</au><au>KAMEN, Douglas E</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R)</title><date>2017-07-13</date><risdate>2017</risdate><abstract>Se refiere a una formulacion farmaceutica que comprende: (i) un anticuerpo humano que se une de modo especifico al receptor de interleuquina-6-humana (hIL-6R) a una concentracion de 25 mg/ml a 200 mg/ml y comprende una region variable donde la cadena pesada comprende la secuencia SEQ ID NO: 18 y la cadena ligera, la secuencia SEQ ID NO: 26; (ii) histidina a una concentracion de 10 mM a 25 mM; (iii) arginina a una concentracion de 25 mM a 50 mM; (iv) sacarosa en una cantidad de 5% a 10 %; y (v) polisorbato 20 en una cantidad de 0,2%. Dicha formulacion muestra un grado sustancial de estabilidad del anticuerpo despues de una conservacion durante varios meses
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_PE20170948A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | FORMULACIONES ESTABILIZADAS QUE CONTIENEN ANTICUERPOS ANTI-RECEPTOR DE INTERLEUQUINA-6 (IL-6R) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A01%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GRAHAM,%20Kenneth%20S&rft.date=2017-07-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPE20170948A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |